Hormonal
Chronic oral consumption of thermally processed foods containing advanced glycation endproducts (AGEs) promotes insulin resistance and type 2 diabetes by depleting the antioxidant defenses AGE receptor-1 (AGER1) and sirtuin 1 (SIRT1).
To support your metabolic health, reduce your intake of advanced glycation endproducts (AGEs) by modifying how you cook. Prioritize moist cooking methods like stewing, boiling, or poaching over dry, high-heat methods like grilling, frying, or broiling. Avoid browning or charring foods, as this process significantly increases AGE formation. This simple shift can help preserve your body's natural antioxidant defenses (AGER1 and SIRT1) and improve insulin sensitivity.
We propose that chronic ingestion of oral AGEs promotes IR and T2D. The mechanism(s) involved in these findings were assessed in four generations of C57BL6 mice fed isocaloric diets with or without AGEs [synthetic methyl-glyoxal-derivatives (MG+)]. F3/MG+ mice manifested increased adiposity and premature IR, marked by severe deficiency of anti-AGE advanced glycation receptor 1 (AGER1) and of survival factor sirtuin 1 (SIRT1) in white adipose tissue (WAT), skeletal muscle, and liver.
Why this rating
High-quality mechanistic data from multi-generational mouse studies and in vitro cell models, though not a direct human clinical trial.
Source
Oral advanced glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1
Weijing Cai et al. · Proceedings of the National Academy of Sciences · 2012
DOI 10.1073/pnas.1205847109
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →